Deb Jorn

Deb has over 30 years of commercial experience building specialty pharmaceutical businesses across numerous therapeutic areas. She is currently EVP of Corporate and Commercial Development at pSivida Corp. a specialty pharmaceutical company focused on the development of proprietary sustained-released drug delivery technology to treat serious back of the eye diseases. Prior to joining pSivida, Deb was Executive Vice President and Group Company Chair at Valeant and previously served as Chief Marketing Officer at Bausch & Lomb where she led the successful launches of Lotemax gel, Prolensa and Zirgan. Earlier, Deb was Group Vice President of Women’s Healthcare and Fertility at Schering Plough Corporation. She was also at Johnson & Johnson as the Worldwide VP of Internal Medicine and Early Commercial input. She began her career at Merck and for more than 20 years held roles of progressive responsibility in various functional areas including R&D, Regulatory and Sales and Marketing. Deb holds a BA in Biochemistry from Rutgers University and an MBA from NYU Stern School of Business.